The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Hallucinogen persisting perceptual disorder: a scoping review covering frequency, risk factors, prevention, and treatment
Abstract
INTRODUCTION: Hallucinogen persisting perception disorder (HPPD) affects a subset of persons who use hallucinogens and is defined as the repeated experience of hallucinations and other perceptual disturbances as a result of prior intoxications. As select hallucinogens are under development for the treatment of selectmental disorders, there is a need to better characterize this disorder. AREAS COVERED: A scoping review of the literature on HPPD was completed from inception to July 2021. Topics covered in the review herein include treatments for HPPD, prevalence or incidence data on HPPD among different classes of hallucinogens, risk factors for HPPD, and data pertaining to the pathophysiology of HPPD. EXPERT OPINION: Hallucinogen persisting perception disorder appears to be an uncommon yet serious event associated with prior hallucinogen exposure. The renewed interest in psychedelics as potential treatment options for select mental disorders, especially agents with hallucinogenic potential, provides the impetus to characterize HPPD in its frequency, risk and protective factors, key characteristics, as well as other clinical and treatment-related factors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation
Tricco, A. C., Lillie, E., Zarin, W., O'Brien, K. K., Colquhoun, H., Levac, D., Moher, D., Peters, M. D. J., Horsley, T., Weeks, L., et al. (2018) · Annals of Internal Medicine · doi:10.7326/m18-0850 · Cited by 43,565
Scoping studies: towards a methodological framework
Arksey, H., & O'Malley, L. (2005) · International Journal of Social Research Methodology · doi:10.1080/1364557032000119616 · Cited by 36,742 · cited 2×
“A broad research question was identified for this scoping review in accordance with recommendations outlined by Arkley and O’Malley [13], and follows as what information do we already know about HPPD that can help clinicians who encounter this disorder during their practice? Recognizing clinicians would want to know m…”
MethodStang, A. (2010) · European Journal of Epidemiology · doi:10.1007/s10654-010-9491-z · Cited by 17,396
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
Biological studies of post-traumatic stress disorder
Pitman, R. K., Rasmusson, A. M., Koenen, K. C., Shin, L. M., Orr, S. P., Gilbertson, M. W., Milad, M. R., & Liberzon, I. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3339 · Cited by 1,529
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial
Davis, A. K., Barrett, F. S., May, D. G., Cosimano, M. P., Sepeda, N. D., Johnson, M. W., Finan, P. H., & Griffiths, R. R. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3285 · Cited by 1,301
The Pharmacology and Clinical Pharmacology of 3,4-Methylenedioxymethamphetamine (MDMA, “Ecstasy”)
Green, A. R., Mechan, A. O., Elliott, J. M., O’Shea, E., & Colado, M. I. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.3.3 · Cited by 1,272
Chapter 7: Systematic reviews of etiology and risk
(2020) · JBI Manual for Evidence Synthesis · doi:10.46658/jbimes-20-08 · Cited by 1,268
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970 · cited 1×
“Several cases of HPPD have been reported to occur after only one occasion of hallucinogen usage [8],”
Background
Research works printed but not linked: 12
- Lerner A, 2014, Isr J Psychiatry Relat Sci, 51, 296
- 2013, Diagnostic and statistical manual of mental disorders
- Levels of Evidence Working Group, 2011, The Oxford 2011 levels of evidence
- Kurtom M, 2019, Cureus, 11, e4077
- Lerner A, 2014, J Psychiatry, 51, 307
- Lerner AG, 1998, J Psychiatry, 155, 1460
- Lerner AG, 1997, J Psychiatry, 154, 437
- Lerner AG, 2001, J Psychiatry, 38, 133
- Lerner AG, 2002, J Psychiatry, 39, 100
- Lerner A, 2015, J Psychiatry, 52, 67
- Lerner A, 2014, J Psychiatry, 51, 277
- Casa B, 1589, J Neurol Sci, 2005, S504
Cited by
Rosenblat, J. D., Husain, M. I., Lee, Y. L., McIntyre, R. S., Mansur, R. B., Castle, D. J., Offman, H., Parikh, S. V., Frey, B. N., Schaffer, A., et al. (2022) · The Canadian Journal of Psychiatry · doi:10.1177/07067437221111371 · Cited by 76
Self-citationSabé, M., Sulstarova, A., Glangetas, A., Pieri, M. D., Mallet, L., Curtis, L., Richard-Lepouriel, H., Penzenstadler, L. E., Seragnoli, F., Thorens, G., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02800-5 · Cited by 71
Wolf, G., Singh, S., Blakolmer, K., Lerer, L. B., Lifschytz, T., Heresco‐Levy, U., Lotan, A., & Lerer, B. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01832-z · Cited by 52
McIntyre, R. S., Kwan, A. T. H., Mansur, R. B., Oliveira-Maia, A. J., Teopiz, K. M., Maletic, V., Suppes, T. M., Stahl, S. M., & Rosenblat, J. D. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230902 · Cited by 37
Self-citationInformed Consent to Psychedelic-Assisted Psychotherapy: Ethical Considerations
Lee, A., Rosenbaum, D., & Buchman, D. Z. (2024) · The Canadian Journal of Psychiatry · doi:10.1177/07067437231225937 · Cited by 35
Metadata
- Authors
- Doyle, M. A., Ling, S., Lui, L. M. W., Fragnelli, P., Teopiz, K. M., Ho, R., Di Vincenzo, J. D., Rosenblat, J. D., Gillissie, E. S., Nogo, D., Ceban, F., Jawad, M. Y., & McIntyre, R. S.
- Affiliations
- Western University (CA)
- University Health Network (CA)
- National University of Singapore (SG)
- Mood Disorders Psychopharmacology Unit, Poul Hansen Depression Centre, University Health Network Toronto, ON, Canada
- Corresponding author
- Doyle, Marcus A.
- ORCID
- Venue
- Expert Opinion on Drug Safety
- Publisher
- Informa UK Limited
- Published
- 2022-05-03
- Volume
- 21
- Issue
- 6
- Pages
- 733-743
- ISSN
- 1474-0338 (ISSN-L)
- 1744-764X
- OpenAlex
- W4224043710
- Cited by
- 27
- References
- 46
- Citations by year
- 2026: 6 · 2025: 9 · 2024: 5 · 2023: 5 · 2022: 2
- FWCI
- 0.88
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Opinion on Drug Safety (publishedVersion)
- PubMed (publishedVersion)
- National University of Singapore (submittedVersion)
- Rare & Special e-Zone (The Hong Kong University of Science and Technology) (submittedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cognitive Neuroscience › Hallucinations in medical conditions
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- hallucinogen persisting perception disorder, hallucinogens, psychedelics, prevalence, risk factors, prevention, treatment, pathophysiology, hallucinations, mental illness, drug safety
- MeSH terms
- Hallucinations, Hallucinogens, Humans, Perceptual Disorders, Risk Factors, Prevalence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Hallucinogen persisting perceptual disorder: a scoping review covering frequency, risk factors, prevention, and treatment. https://app.cochat.ai/papers/10.1080/14740338.2022.2063273
- The paper
- Doyle, M. A., Ling, S., Lui, L. M. W., Fragnelli, P., Teopiz, K. M., Ho, R., Di Vincenzo, J. D., Rosenblat, J. D., Gillissie, E. S., Nogo, D., Ceban, F., Jawad, M. Y., & McIntyre, R. S. (2022). Hallucinogen persisting perceptual disorder: a scoping review covering frequency, risk factors, prevention, and treatment. Expert Opinion on Drug Safety. https://doi.org/10.1080/14740338.2022.2063273
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.